Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

EHA 2020

Multiple Myeloma

View all
4:10
KarMMa: idecabtagene vicleucel QoL
Michel Delforge • 15 Jun 2020
1:17
Impact of prior therapies on efficacy of belantamab mafodotin in R/R myeloma
Sagar Lonial • 19 Jun 2020
4:30
IKEMA: kD vs isatuximab and kD in R/R myeloma
Philippe Moreau • 16 Jun 2020
7:57
Updates on DREAMM-6 and DREAMM-2 in R/R myeloma
Rakesh Popat • 12 Jun 2020

CLL

View all
4:13
Front-line and R/R updates in CLL from EHA
Peter Hillmen • 17 Jun 2020
5:54
Updates from CAPTIVATE: ibrutinib and venetoclax for CLL
Tanya Siddiqi • 17 Jun 2020
4:30
CLL14 trial: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil
Othman Al-Sawaf • 14 Jun 2020
3:15
Umbralisib with ibrutinib in patients with R/R CLL or MCL
Matthew Davids • 11 Jun 2020

Lymphoma

View all
5:39
Acalabrutinib monotherapy in mature B-cell malignancies
Richard Furman • 10 Jun 2020
2:16
ALEXANDER: bicistronic CD19 & CD22 CAR for DLBCL
Wendy Osborne • 1 Jun 2020
4:07
HD17: PET guided omission of radiotherapy in Hodgkin lymphoma
Peter Borchmann • 3 Jun 2020
10:56
Liso-cel for second-line R/R aggressive large B-cell NHL
Nilanjan Ghosh • 18 Jun 2020

MDS

View all
2:05
Venetoclax with decitabine for high-risk AML and MDS
Abhishek Maiti • 2 Jun 2020
6:51
Anti-TIM-3 antibody sabatolimab + hypomethylating agents for high-risk MDS & AML
Uma Borate • 8 Jun 2020

ALL

View all
5:46
The role of the gut microbiome in protecting genetically predisposed mice against leukemia
Carolina Vicente-Dueñas • 28 May 2020
4:03
FORUM: total body irradiation vs chemotherapy in pediatric ALL
Christina Peters • 11 Jun 2020

AML

View all
2:05
Venetoclax with decitabine for high-risk AML and MDS
Abhishek Maiti • 2 Jun 2020
2:16
Rationale for 10-day decitabine with venetoclax for high-risk AML
Abhishek Maiti • 1 Jun 2020
6:21
Decitabine and venetoclax for AML
Abhishek Maiti • 1 Jun 2020
9:17
Comparing outcomes of 10-day decitabine with venetoclax vs. chemotherapy in AML based on fitness
Abhishek Maiti • 2 Jun 2020

MPNs

View all
3:39
Efficacy of navitoclax with ruxolitinib in myelofibrosis patients
Claire Harrison • 5 Jun 2020
1:53
Parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib
Abdulraheem Yacoub • 12 Jun 2020
3:49
Second primary malignancy after treatment with ruxolitinib
Francesca Palandri • 16 Jun 2020
1:24
Imetelstat in high-risk triple-negative myelofibrosis
Jean-Jacques Kiladjian • 15 Jun 2020

Immuno-Oncology

View all
4:23
LYSA: atezolizumab, obinutuzumab and venetoclax in R/R DLBCL
Charles Herbaux • 10 Jun 2020
3:52
Myeloma: immunotherapy updates from EHA 2020
Mohamad Mohty • 9 Jun 2020
6:01
CD19 CAR-T for lymphoma: real-world experience in the UK
Andrea Kuhnl • 14 Jun 2020
2:16
ALEXANDER: bicistronic CD19 & CD22 CAR for DLBCL
Wendy Osborne • 1 Jun 2020

COVID-19 & Hematological Malignancy

View all
2:23
John Gribben talks on Coronavirus
John Gribben • 27 Apr 2020
4:00
Positive learnings in myeloma management to come out of COVID-19 pandemic
Mohamad Mohty • 9 Jun 2020
2:00
Impact of COVID-19 on treatment of B-cell malignancies
Arnon Kater • 8 Jun 2020
2:56
Managing lymphoma during the COVID-19 pandemic
Peter Borchmann • 3 Jun 2020

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals